Research

January 9, 2023

Novel lung cancer biomarker

Autoantibodies against the p53 tumor suppressor protein may be a novel biomarker for identifying people, especially African Americans, at high risk for lung cancer.

By Leigh MacMillan
January 6, 2023

Early effects of Huntington disease

Impairments in brain executive function happen earlier than motor symptoms in people with the gene mutation that causes Huntington disease, suggesting younger ages and cognitive symptoms be considered for any future clinical trials.

By Kelsey Pinckard
January 6, 2023

MicroRNAs linked to lipid damage

VUMC researchers have linked microRNAs with systemic lipid peroxidation, a discovery that could point to new therapeutic targets for a variety of diseases.

By Sarah E. Glass
The study team included, from left, Raymond Harris, MD, J.P. Arroyo, MD, PhD, and Gautam Bhave, MD, PhD.
January 5, 2023

VUMC researchers upend dogma about vasopressin production

Vanderbilt investigators have discovered that vasopressin, which has long been thought to be produced only in the brain, is also produced in the kidney.

By Leigh MacMillan
December 28, 2022

Vanderbilt mourns loss of renowned scientist Exton

John H. Exton, MBChB, MD, PhD, professor of Molecular Physiology and Biophysics, emeritus at Vanderbilt University, whose research provided fundamental insights into how many biologically active compounds control cellular physiology, died Dec. 18. He was 89.

By Bill Snyder
Gordon Bernard, MD, is stepping down from his institutional leadership roles next summer to focus on his research interests.
December 16, 2022

VUMC Announces VICTR Leadership Transition

By Bill Snyder
December 15, 2022

Novel therapeutic target identified for chronic kidney disease

Vanderbilt investigators have discovered a molecular mechanism that promotes chronic kidney disease following kidney injury.
By Leigh MacMillan
December 15, 2022

Reduced kidney function may cause cardiovascular disease: study

An international team of investigators has found that mild to moderate reduction in kidney function may cause cardiovascular disease, even in people without symptoms of heart disease or diabetes.
By Bill Snyder
December 15, 2022

Dooley honored by Treatment Action Group

Vanderbilt's Kelly Dooley, MD, PhD, MPH, recently received the Research in Action Award from the Treatment Action Group (TAG).
By Paul Govern
December 14, 2022

Surgical risk persists for patients who’ve had COVID

Vanderbilt researchers report that the trend of decreasing postoperative risk for people who have had COVID persists longer than previously known, for as long as 13 months after COVID.
By Paul Govern
December 8, 2022

Researchers develop framework for multiancestry genomic studies

Vanderbilt researchers have developed a framework for the analysis of multiancestry, large-scale genomic studies across multiple biobanks.
By Leigh MacMillan
November 30, 2022

Study links excess oxygen during anesthesia to risk of organ injury

A Vanderbilt study found that higher levels of excess oxygen given to patients under general anesthesia add risk of injury to the kidneys, lungs and heart.
By Paul Govern
November 22, 2022

Risk score for muscular dystrophy

An imaging-based risk score can identify patients with Duchenne muscular dystrophy who are at greater risk of early mortality, allowing more intensive treatment and potentially prolonging life.
By Kelsey Pinckard
1 … 26 27 28 29 30 … 125